Catch up on the essentials
- UnitedHealth delivered third-quarter 2026 revenue of about $113 billion and adjusted earnings per share of $4.69, up from $2.92 a year earlier, as the company lifted its full-year 2026 adjusted EPS guidance to at least $20.50 (MarketBeat; BigGo).
- Medicare Advantage margins are now expected to settle near the top of the insurer's 2%–4% target band for the year, and Medicaid is described as a trough year with margins moderately better than negative 1% (BigGo; Yahoo Finance/Moby Intelligence).
- Through the third quarter, UnitedHealth repurchased $5 billion of stock and paid $6.2 billion in dividends year to date, with full-year dividends expected to exceed $8 billion (MarketBeat).
Selected from this article · 2026-10-13
Read on for the full pictureQ3 results and the 2026 outlook lift
UnitedHealth delivered third-quarter 2026 revenue of about $113 billion and adjusted earnings per share of $4.69, up from $2.92 a year earlier, as the company lifted its full-year 2026 adjusted EPS guidance to at least $20.50 (MarketBeat; BigGo). The medical care ratio improved 150 basis points year over year to 88.4%, signaling firmer pricing discipline across UnitedHealthcare and Optum (MarketBeat; BigGo; stockanalysis.com). Management framed the quarter as evidence that leadership and execution have stabilized after several uneven periods.
Where the beat came from, and where costs still bite
The consolidated result masked a segmented picture. Medicare Advantage margins are now expected to settle near the top of the insurer's 2%–4% target band for the year, and Medicaid is described as a trough year with margins moderately better than negative 1% (BigGo; Yahoo Finance/Moby Intelligence). Commercial medical costs remained under pressure, with trends north of 11% driven by No Surprises Act arbitration awards, clinician cost intensity, and specialty drug pricing (BigGo; MarketBeat; stockanalysis.com). Within Optum, Optum Rx crossed a milestone with external membership surpassing 50% for the first time, Optum Health logged a 27% jump in online self-scheduling and a 10% rise in home-health visits, and Optum Insight was positioned as a multi-year AI-first product story (BigGo; Yahoo Finance/Moby Intelligence).
AI and prior-authorization rollout reshape the cost structure
Management used the call to accelerate operational changes that anchor its 2027 outlook, including AI-enabled chart summarization now used by more than 40% of employed clinicians, cutting chart review time by 33%, and AI-enabled information gathering that shortened appeal cycle times by 26% (stockanalysis.com). UnitedHealth said it remains on track to complete all previously announced prior-authorization reforms by year-end, which the company expects will reduce total authorizations by 30%, including a two-thirds reduction for people under 18 (stockanalysis.com). CEO Steve Hemsley tied the modernization push directly to value-based care expansion and a simpler clinician experience (stockanalysis.com; MarketBeat).
Capital return signals confidence, alongside funding cautions
Through the third quarter, UnitedHealth repurchased $5 billion of stock and paid $6.2 billion in dividends year to date, with full-year dividends expected to exceed $8 billion (MarketBeat). Debt-to-capital stood at 41.7% at quarter-end, with management saying it remains on track to approach 40% by year-end (MarketBeat; BigGo). CFO Wayne DeVeydt also cautioned on health-benefit funding pressures that are shaping commercial pricing decisions, even as the company raised its profit outlook (MarketBeat; BigGo).
2027 is the proving ground for 13%–16% growth
Hemsley said actions taken during 2026 have strengthened confidence in returning to the long-term 13%–16% adjusted EPS growth target beginning in 2027, with DeVeydt calling the lower end of that range "a more reasonable starting point" than current analyst consensus (MarketBeat; BigGo; Yahoo Finance/Moby Intelligence). The next observable checkpoint is the full-year 2026 results release, which will establish whether the raised guidance and AI-enabled cost levers translate into the margin trajectory management has now committed to for 2027.
Related industries and supply products
Industry / product or service | Evidence level | Event connection | Verification signal | Main risk |
|---|---|---|---|---|
Healthcare IT and AI clinical tooling | confirmed | Management tied AI chart summarization and prior-authorization reforms to Q3 efficiency gains (stockanalysis.com) | Disclosure of rollout percentage, cycle-time reduction, and 2027 product acceleration on next earnings call | ROI and clinician adoption slippage |
Pharmacy benefit management and specialty pharmacy | confirmed | Optum Rx external membership topped 50%; specialty drug costs flagged as a commercial trend driver (BigGo; MarketBeat) | External-membership mix disclosed in subsequent quarterly filings | Continued specialty drug cost inflation |
Medical cost management services | research watchlist | No Surprises Act arbitration and clinician cost intensity cited as commercial cost drivers (BigGo; MarketBeat) | Regional arbitration share disclosure; commercial medical loss ratio trajectory in 2027 guidance | Persistent cost trend above 11% erodes margin lift |
No procurement has been confirmed through today's earnings materials; the AI, PBM and cost-management rows above reflect product categories named or implied on the call, not orders.
Share this article
